Pharmaceutical - KYTHERA Biopharmaceuticals


Popular Filters

KYTHERA submental fat drug candidate meets all primary endpoints in Ph III


US biotech firm KYTHERA Biopharmaceuticals (Nasdaq: KYTH) saw its stock upgraded to $50 a share from…

ATX-101BayerDermatologicalsKYTHERA BiopharmaceuticalsPharmaceuticalResearch

Significant and sustainable reduction in "double chin" with Bayer's ATX-101


German drug major Bayer's (BAYN: DE) investigational drug ATX-101 can significantly and sustainably reduce…

ATX-101BayerDermatologicalsKYTHERA BiopharmaceuticalsPharmaceuticalResearch

Positive results for KYTHERA and Bayer's ATX-101 in the reduction of "double chin"


Privately-held US biotech firm KYTHERA Biopharmaceuticals announced positive interim results from a Phase…

ATX-101BayerDermatologicalsKYTHERA BiopharmaceuticalsPharmaceuticalResearch

KYTHERA Biopharma gets $33.3 million in payments from Bayer


Privately-held US biotech firm KYTHERA Biopharmaceuticals says it has received a $15.8 million payment…

BayerBiotechnologyFinancialKYTHERA BiopharmaceuticalsLicensingPharmaceuticalResearch

Back to top